Sight Sciences (NASDAQ:SGHT) PT Raised to $10.00 at Citigroup

Sight Sciences (NASDAQ:SGHTGet Rating) had its price objective raised by investment analysts at Citigroup to $10.00 in a report issued on Wednesday, Stock Target Advisor reports. Citigroup’s price target indicates a potential downside of 2.34% from the company’s current price.

A number of other analysts also recently issued reports on the stock. William Blair reissued an “outperform” rating on shares of Sight Sciences in a report on Thursday, November 10th. Bank of America began coverage on shares of Sight Sciences in a research report on Tuesday, October 11th. They set a “neutral” rating for the company. Morgan Stanley upped their price objective on shares of Sight Sciences from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Friday, November 11th. Piper Sandler reduced their price objective on shares of Sight Sciences from $17.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, August 12th. Finally, Stifel Nicolaus restated an “initiates” rating on shares of Sight Sciences in a research report on Tuesday, July 26th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Sight Sciences Stock Performance

Shares of NASDAQ SGHT opened at $10.24 on Wednesday. The company’s fifty day moving average price is $7.25 and its 200 day moving average price is $8.26. Sight Sciences has a 1 year low of $5.35 and a 1 year high of $23.03. The company has a market capitalization of $493.07 million, a PE ratio of -5.76 and a beta of 1.21. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.47 and a current ratio of 12.79.

Institutional Investors Weigh In On Sight Sciences

Hedge funds have recently modified their holdings of the business. Amalgamated Bank acquired a new stake in shares of Sight Sciences in the first quarter valued at about $31,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Sight Sciences in the third quarter valued at about $37,000. Quantbot Technologies LP acquired a new stake in shares of Sight Sciences in the third quarter valued at about $43,000. FMR LLC raised its position in shares of Sight Sciences by 484.6% in the second quarter. FMR LLC now owns 4,864 shares of the company’s stock valued at $44,000 after buying an additional 4,032 shares during the last quarter. Finally, Algert Global LLC acquired a new stake in shares of Sight Sciences in the third quarter valued at about $81,000. 65.20% of the stock is currently owned by institutional investors and hedge funds.

About Sight Sciences

(Get Rating)

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.

Recommended Stories

Stock Target Advisor logo

Analyst Recommendations for Sight Sciences (NASDAQ:SGHT)

Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.